Skip to main content
OpenTrials
Completed

NCT Number: NCT00777907

Complete Occlusion of Coilable Aneurysms

To compare the safety and effectiveness of Pipeline Embolization Device to coil embolization for the treatment of coilable wide-necked intracranial aneurysms

Completed

Looking for future studies?

Notify Me

Key information

Age range

21 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Barrow Neurological Institute, Phoenix, Arizona, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 21 to 75 years, inclusive
  • Patient has a single target IA that:
  • is located in the following regions of the internal carotid artery: i. Paraophthalmic (including paraclinoid, ophthalmic and hypophyseal segments) ii. Cavernous iii. Petrous
  • is saccular
  • has a parent vessel with diameter 2.5-5.0 mm
  • If target IA has a neck >4 mm, at least 2 of 3 members of an independent expert committee (IEC) have confirmed that coil embolization with optional adjunctive techniques** has a very high likelihood of procedural success (i.e., coil placement and retention)
  • Subject has provided written informed consent using the IRB-approved consent form
  • Subject has the necessary mental capacity to participate and is willing and able to comply with protocol requirements
  • ** Adjunctive techniques include intravascular balloons ["balloon remodeling"], 3D coils, dual catheter techniques.

Exclusion criteria

  • Target IA has BOTH neck >4 mm AND size (maximum fundus diameter) >10 mm
  • More than one IA requires treatment in the next 6 months
  • Subarachnoid hemorrhage in the past 60 days
  • Any intracranial hemorrhage in the last 42 days
  • Major surgery in the last 42 days
  • Coils in place in the target IA
  • Unstable neurologic deficit (i.e., any worsening of clinical condition in the last 30 days)
  • Known irreversible bleeding disorder
  • Platelet count < 100 x 103 cells/mm3 or known platelet dysfunction
  • Inability to tolerate, documented evidence of adverse reaction or contraindication to study medications
  • Prior stent placement at target site
  • Contraindication to CT scan AND MRI
  • Known allergy to contrast used in angiography that cannot be medically controlled
  • Known severe allergy to platinum or cobalt/chromium alloys
  • Relative contraindication to angiography (e.g., serum creatinine > 2.5 mg/dL)
  • Woman of child-bearing potential who cannot provide a negative pregnancy test
  • Evidence of active infection at the time of treatment
  • Other known conditions of the heart, blood, brain or intracranial vessels that carry a high risk of neurologic events (e.g., severe heart failure, atrial fibrillation, known carotid stenosis)
  • Current use of cocaine or other illicit substance
  • Any comorbid disease or condition expected to compromise survival or ability to complete follow-up assessments to 180 days
  • Extracranial stenosis greater than 50% in the carotid artery
  • Intracranial stenosis greater than 50% in the treated vessel

Treatment and study plan

Pipeline Embolization Device (PED)

Device

1 or more PEDs placed in the parent artery of the affected aneurysm via endovascular approach.

Other names: Pipeline Embolization Device, PED

Coil embolization

Device

Placement of bare platinum coils into the target aneurysm with balloon remodeling allowed.

Primary outcomes

  1. Effectiveness: Proportion of subjects whose target aneurysm shows complete occlusion on angiogram with <=50% stenosis of the parent artery. Safety: Proportion of subjects with ipsilateral major stroke or neurologic death.

    Time frame: 180 days

Secondary outcomes

  1. Rate of complete target aneurysm occlusion

    Time frame: 1, 3 and 5 years

  2. Incidence of ipsilateral major stroke

    Time frame: 180 days

  3. Change in modified Rankin scale (MRS)

    Time frame: 180 days, 1, 3 and 5 years

  4. Incidence of device-related adverse events

    Time frame: 180 days, 1, 3 and 5 years

  5. Change from baseline in neurologic signs or symptoms related to the target aneurysm

    Time frame: 180 days

Sponsors and collaborators

Lead sponsor

Chestnut Medical Technologies

Industry

Registry information

Acronym: COCOA

Important dates

Study start
2008
Primary completion
2014
Study completion
2015
First posted
Oct 22, 2008
Registry last updated
Aug 7, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.